A trial evaluating the reduction in inflammation in patients with advanced chronic renal disease using antibody-mediated IL-6 inhibition (RESCUE) is an ongoing phase II trial intended to demonstrate the cardiovascular benefit of IL-6 inhibition by ziltivekimab [58]. This evidence concerns the gene IL6 and chronic kidney disease.